Press Releases on December 11, 2022 - EIN Presswire - Press Release Distribution Service

Published on December 11, 2022 - 16:38 GMT

Baltimore Sun Names Primary Residential Mortgage, Inc. a Winner of the Regional Top Workplaces 2022 Award

PRMI receives prestigious top employer award for fourth year in a row. BALTIMORE, Dec. 11, 2022 /PRNewswire-PRWeb/ -- Primary Residential Mortgage, Inc. (PRMI) is thrilled to announce its Baltimore Division has been awarded two Top Workplaces 2022 honors …

Distribution channels: Banking, Finance & Investment Industry

Published on December 11, 2022 - 16:38 GMT

Aptose Announces Updated Clinical Responses, Breadth of Activity, and Safety Across Four Dose Levels of Tuspetinib in Difficult-to-...

Company Provides Comprehensive Clinical Update from Phase 1/2 Trial Tuspetinib Continues to Deliver Single Agent Responses in r/r AML Patients Tuspetinib Safety and Efficacy Profile may Position Drug to Become the Preferred Kinase Inhibitor for Triplet …

Distribution channels: Banking, Finance & Investment Industry

Published on December 11, 2022 - 16:38 GMT

Rent the Runway Deadline Alert

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Rent the Runway To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - December 11, 2022) - Faruqi & …

Distribution channels: Banking, Finance & Investment Industry

Published on December 11, 2022 - 16:38 GMT

Bellicum Announces Presentation by UNC at ASH 2022 on Potential Abrogation of iC9 CAR T-Cell Toxicities with Rimiducid

HOUSTON, Dec. 11, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. BLCM, a leader in developing novel, controllable cellular immunotherapies for cancers, today announced a poster presentation by the University of North Carolina Lineberger …

Distribution channels: Banking, Finance & Investment Industry

Published on December 11, 2022 - 16:38 GMT

Graphite Bio Presents Preclinical Data for Novel Sequencing Method Used to Determine Gene Editing Outcomes at 64th ASH Annual ...

Single-cell RNA sequencing of reticulocytes will be used to measure gene correction outcomes in sickle cell patients treated with nulabeglogene autogedtemcel (nula-cel) Graphite Bio, Inc. GRPH, a clinical-stage, next-generation gene editing company …

Distribution channels: Banking, Finance & Investment Industry

Published on December 11, 2022 - 16:38 GMT

MaaT Pharma Presents Promising Detailed Results from Completed Phase 1b Trial with MaaT033 at the 64th ASH Annual Meeting

Detailed results from completed Phase 1b CIMON trial in 21 acute myeloid leukemia (AML) patients treated with the company's Microbiome Ecosystem TherapyTM (MET) oral capsule, MaaT033, demonstrating its safety and ability to increase gut microbiota …

Distribution channels: Banking, Finance & Investment Industry

Published on December 11, 2022 - 16:38 GMT

Time to CAR T-cell Therapy May Impact Outcomes for Patients With Relapsed/Refractory Large B-cell Lymphoma in New CIBMTR Analysis

– Kite's Manufacturing Time for Yescarta® in the U.S. is Median of 7-Days from Start of Cell Enrichment to Harvest, with an Overall 16-Day Turnaround Time (Leukapheresis to Product Release) – – CIBMTR Analysis Finds Median ‘Vein-to-Vein' Time ( …

Distribution channels: Banking, Finance & Investment Industry

Published on December 11, 2022 - 16:38 GMT

ROSEN, NATIONAL INVESTOR COUNSEL, Encourages NewAge Inc. Investors to Secure Counsel Before Important Deadline in First Filed ...

New York, New York--(Newsfile Corp. - December 11, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the securities of NewAge, Inc. NBEV NBEVQ between January 18, 2018 …

Distribution channels: Banking, Finance & Investment Industry

Published on December 11, 2022 - 16:38 GMT

Wugen Presents Data Supporting Clinical Development of WU-NK-101 for Relapsed / Refractory AML at the American Society of ...

– Genetic tumor microenvironment (TME) signature identified as highly predictive of duration of response to cytokine-induced memory-like (CIML) NK cell therapy – – WU-NK-101 exhibited enhanced anti-tumor activity, robust bone marrow trafficking, and …

Distribution channels: Banking, Finance & Investment Industry

Published on December 11, 2022 - 16:38 GMT

Kymera Therapeutics Presents Preclinical Data Demonstrating Activity of KT-253, a Selective Heterobifunctional MDM2 Degrader, in ...

A single dose of KT-253 induced rapid apoptosis and sustained tumor regression in xenograft models of AML KT-253 showed combinatorial benefit with BCL-2 inhibitor venetoclax in model of venetoclax-resistant AML KT-253 also active in other hematologic …

Distribution channels: Banking, Finance & Investment Industry

Published on December 11, 2022 - 16:37 GMT

Vincerx Pharma Presents Preclinical Data on VIP943 in Acute Myeloid Leukemia Models at the 64th American Society of Hematology ...

Vincerx's proprietary payload and linker technology and VIP943, a novel anti-CD123 antibody drug conjugate (ADC), demonstrated superiority with significant improved safety in non-human primates (NHP) when compared with Mylotarg™ (gemtuzumab ozogamicin) …

Distribution channels: Banking, Finance & Investment Industry

Published on December 11, 2022 - 16:38 GMT

Kronos Bio Presents Preclinical Data Supporting Anti-Leukemic Activity of Lanraplenib in Combination with Multiple Targeted Agents ...

Lanraplenib is being evaluated in ongoing Phase 1b/2 trial in combination with gilteritinib in patients with relapsed/refractory FLT3-mutated AML Additional presentations highlight Kronos Bio's collaboration with academic cooperative groups to better …

Distribution channels: Banking, Finance & Investment Industry

Published on December 11, 2022 - 16:38 GMT

IGM Biosciences Presents Data from T cell Engager Portfolio for Hematologic Malignancies at 2022 American Society of Hematology ...

MOUNTAIN VIEW, Calif., Dec. 11, 2022 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. IGMS, a clinical-stage biotechnology company focused on creating and developing IgM antibodies, today announced the presentation of data from IGM's expanding portfolio of T …

Distribution channels: Banking, Finance & Investment Industry

Published on December 11, 2022 - 16:38 GMT

Harpoon Therapeutics Presents Updated Interim Results at ASH 2022 for Novel T Cell Engager HPN217 in Relapsed/Refractory Multiple ...

Clinically active across a wide dose range (2.15 to 24 mg) in a Phase 1 trial of heavily pretreated patients with relapsed/refractory multiple myeloma 77% (10/13) objective response rate (ORR) observed across highest doses (12 and 24 mg) Responses were …

Distribution channels: Banking, Finance & Investment Industry

Published on December 11, 2022 - 16:37 GMT

ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Polished.com Inc. f/k/a 1847 Goedeker Inc. Investors With Losses to Secure Counsel ...

New York, New York--(Newsfile Corp. - December 11, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Polished.com Inc. f/k/a 1847 Goedeker Inc. POL GOED: (i) pursuant and/or traceable to the …

Distribution channels: Banking, Finance & Investment Industry

Published on December 11, 2022 - 16:37 GMT

Ryvu Therapeutics Presents Clinical and Translational Data of RVU120 and SEL24 (MEN1703) at the 2022 American Society of ...

RVU120 Demonstrates Single-Agent Activity with a Complete Response, 4 Blast Reductions, and 4 Erythroid and/or Platelet responses in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (HR-MDS); Preclinical …

Distribution channels: Banking, Finance & Investment Industry

Published on December 11, 2022 - 16:37 GMT

Poseida Therapeutics Presents Preclinical Data from P-FVIII-101 Gene Therapy for Hemophilia A at the 64th ASH Annual Meeting & ...

Data demonstrate that a non-viral, liver-directed gene therapy utilizing Super piggyBac® (SPB) DNA Modification System achieved and maintained normalized human FVIII (hFVIII) activity following a single dose Data establishes preclinical proof of principle …

Distribution channels: Banking, Finance & Investment Industry

Published on December 11, 2022 - 16:37 GMT

Pivotal Odronextamab (CD20xCD3) Phase 2 Data in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma Debut at ASH

49% objective response rate (ORR) in heavily pre-treated patients who were naïve to prior CAR-T, with 31% achieving a complete response (CR) Even in patients who received prior CAR-T, 48% ORR and 32% CR observed in a dose expansion cohort from a Phase 1 …

Distribution channels: Banking, Finance & Investment Industry

Published on December 11, 2022 - 16:37 GMT

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Silvergate Capital Corporation Investors with Losses in Excess of $100K to Secure ...

New York, New York--(Newsfile Corp. - December 11, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Silvergate Capital Corporation SI between …

Distribution channels: Banking, Finance & Investment Industry

Published on December 11, 2022 - 16:37 GMT

Austin Accident Lawyer Podcast Talks Car and Truck Accidents and Insurance Claims

"Austin Accident Lawyer" Andrew Traub shares how his firm has helped their clients get past low insurance policy limits, and gave insights on how his firm has gotten past artificially low insurance caps that prevent injured clients from getting …

Distribution channels: Banking, Finance & Investment Industry